Venketasubramanian Narayanaswamy, Agustin Sherwin Joy, Padilla Jorge L, Yumul Maricar P, Sum Christina, Lee Sze Haur, Ponnudurai Kuperan, Gan Robert N
Raffles Neuroscience Centre, Raffles Hospital, Singapore 188770, Singapore.
Research Department, National Neuroscience Institute, Singapore 188770, Singapore.
J Cardiovasc Dev Dis. 2022 May 12;9(5):156. doi: 10.3390/jcdd9050156.
"Aspirin resistance" (AR) is associated with increased risk of vascular events. We aimed to compare different platelet function tests used in identifying AR and assess their implications on clinical outcome. We performed platelet aggregation studies on non-cardioembolic ischaemic stroke patients taking aspirin 100 mg/day and 30 non-stroke controls. Data were collected on demographics, vascular risk factors, and concomitant medications. Cut-offs for AR were (1) light transmission aggregometry (LTA) of ≥20% using arachidonic acid (AA), ≥70% using ADP, or ≥60% using collagen; and (2) VerifyNow assay ≥ 550 ARU. Telephone follow-ups were conducted by study staff blinded to AR status to ascertain the occurrence of vascular outcomes (stroke, myocardial infarction, amputation, death). A total of 113 patients were recruited, mean age 65 ± 8 years, 47% women, 45 ± 15 days from index stroke. 50 (44.3%, 95% CI 34.9-53.9) had AR on at least 1 test. Frequency of AR varied from 0% to 39% depending on method used and first vs. recurrent stroke. There were strong correlations between LTA AA, VerifyNow and Multiplate ASPItest (r = 0.7457-0.8893), but fair to poor correlation between LTA collagen and Multiplate COLtest (r = 0.5887) and between LTA ADP and Multiplate ADPtest (r = 0.0899). Of 103 patients with a mean follow up of 801 ± 249 days, 10 (9.7%) had vascular outcomes, of which six had AR by LTA-ADP. AR by LTA-ADP is associated with increased risk of vascular outcome ( = 0.034). Identification of AR is not consistent across different platelet function tests. LTA of ≥70% using 10 µM ADP in post-stroke patients taking aspirin is associated with increased risk of vascular outcome.
“阿司匹林抵抗”(AR)与血管事件风险增加相关。我们旨在比较用于识别AR的不同血小板功能测试,并评估它们对临床结局的影响。我们对每日服用100毫克阿司匹林的非心源性缺血性卒中患者和30名非卒中对照者进行了血小板聚集研究。收集了有关人口统计学、血管危险因素和伴随用药的数据。AR的截断值为:(1)使用花生四烯酸(AA)时透光率比浊法(LTA)≥20%,使用二磷酸腺苷(ADP)时≥70%,或使用胶原蛋白时≥60%;(2)VerifyNow检测≥550 ARU。研究人员对AR状态不知情,通过电话随访以确定血管事件(卒中、心肌梗死、截肢、死亡)的发生情况。共招募了113名患者,平均年龄65±8岁,47%为女性,距首次卒中45±15天。50名(44.3%,95%置信区间34.9 - 53.9)患者至少在一项测试中存在AR。AR的发生率因所用方法以及首次卒中与复发性卒中而异,从0%到39%不等。LTA AA、VerifyNow和Multiplate ASPItest之间存在强相关性(r = 0.7457 - 0.8893),但LTA胶原蛋白与Multiplate COLtest之间以及LTA ADP与Multiplate ADPtest之间的相关性一般至较差(r分别为0.5887和0.0899)。在103名平均随访801±249天的患者中,10名(9.7%)发生了血管事件,其中6名通过LTA - ADP检测存在AR。通过LTA - ADP检测出的AR与血管事件风险增加相关(P = 0.034)。不同血小板功能测试对AR的识别并不一致。在服用阿司匹林的卒中后患者中,使用10µM ADP时LTA≥70%与血管事件风险增加相关。